Patients With COPD Cardiovascular Safety of Tiotropium in

[1]  S. Antoniu.  UPLIFT Study: the effects of long-term therapy with inhaled tiotropium in chronic obstructive pulmonary disease , 2009, Expert opinion on pharmacotherapy.

[2]  C. Pedone,et al.  Tiotropium in chronic obstructive pulmonary disease. , 2009, The New England journal of medicine.

[3]  N. Ambrosino,et al.  Tiotropium and exercise training in COPD patients: Effects on dyspnea and exercise tolerance , 2008, International journal of chronic obstructive pulmonary disease.

[4]  C. Furberg,et al.  Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. , 2008, JAMA.

[5]  A. Pickard,et al.  Risk for Death Associated with Medications for Recently Diagnosed Chronic Obstructive Pulmonary Disease , 2008, Annals of Internal Medicine.

[6]  S. Lanes,et al.  The INSPIRE study: influence of prior use and discontinuation of inhaled corticosteroids. , 2008, American journal of respiratory and critical care medicine.

[7]  A. Lindberg,et al.  Bronchodilator efficacy of tiotropium in patients with mild to moderate COPD. , 2008, Primary care respiratory journal : journal of the General Practice Airways Group.

[8]  N. Anthonisen,et al.  Cardiovascular morbidity and the use of inhaled bronchodilators , 2008, International journal of chronic obstructive pulmonary disease.

[9]  D. Mannino,et al.  Relationship between lung function impairment and incidence or recurrence of cardiovascular events in a middle-aged cohort , 2008, Thorax.

[10]  J. Moita,et al.  Tiotropium improves FEV1 in patients with COPD irrespective of smoking status. , 2008, Pulmonary pharmacology & therapeutics.

[11]  T. To,et al.  Survival with Tiotropium Compared to Long-Acting Beta-2-Agonists in Chronic Obstructive Pulmonary Disease , 2008, COPD.

[12]  G. Criner,et al.  Efficacy of Tiotropium Inhalation Powder in African-American Patients with Chronic Obstructive Pulmonary Disease , 2008, COPD.

[13]  H. Magnussen,et al.  Improvements with tiotropium in COPD patients with concomitant asthma. , 2008, Respiratory medicine.

[14]  E. Bateman,et al.  A randomized study of tiotropium Respimat Soft Mist inhaler vs. ipratropium pMDI in COPD. , 2008, Respiratory medicine.

[15]  T. Seemungal,et al.  The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. , 2008, American journal of respiratory and critical care medicine.

[16]  D. Niewoehner,et al.  Premature discontinuation of patients: a potential bias in COPD clinical trials , 2007, European Respiratory Journal.

[17]  G. Donaldson,et al.  Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD , 2007, European Respiratory Journal.

[18]  D. Price,et al.  Efficacy and safety of tiotropium in COPD patients in primary care – the SPiRiva Usual CarE (SPRUCE) study , 2007, Respiratory research.

[19]  H. Sørensen,et al.  Cardiovascular and respiratory hospitalizations and mortality among users of tiotropium in Denmark , 2007, European Journal of Epidemiology.

[20]  S. Salpeter.  Bronchodilators in COPD: Impact of β-agonists and anticholinergics on severe exacerbations and mortality , 2007, International journal of chronic obstructive pulmonary disease.

[21]  F. Maltais,et al.  A randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary disease. , 2007, Canadian respiratory journal.

[22]  R. Buhl,et al.  Efficacy of tiotropium bromide (Spiriva®) in patients with chronic obstructive pulmonary disease (COPD) of different severities , 2006, Pneumologie.

[23]  C. Wentworth,et al.  Pooled clinical trial analysis of tiotropium safety. , 2006, Chest.

[24]  F. Bart,et al.  The Effect of Tiotropium on Hyperinflation and Exercise Capacity in Chronic Obstructive Pulmonary Disease , 2006, Respiration.

[25]  D. Dusser,et al.  The effect of tiotropium on exacerbations and airflow in patients with COPD , 2006, European Respiratory Journal.

[26]  V. Brusasco,et al.  Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. , 2003, Thorax.

[27]  Judith K Jones,et al.  Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. , 2006, Annals of epidemiology.

[28]  S. Kesten,et al.  Absence of Electrocardiographic Findings and Improved Function with Once‐Daily Tiotropium in Patients with Chronic Obstructive Pulmonary Disease , 2005, Pharmacotherapy.

[29]  D. Niewoehner,et al.  Prevention of Exacerbations of Chronic Obstructive Pulmonary Disease with Tiotropium, a Once-Daily Inhaled Anticholinergic Bronchodilator , 2005, Annals of Internal Medicine.

[30]  F. Maltais,et al.  Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. , 2005, Chest.

[31]  R. Casaburi,et al.  Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. , 2005, Chest.

[32]  John Connett,et al.  The Effects of a Smoking Cessation Intervention on 14.5-Year Mortality , 2005, Annals of Internal Medicine.

[33]  B. Make,et al.  Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD , 2004, European Respiratory Journal.

[34]  R. Zuwallack,et al.  Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. , 2003, Chest.

[35]  P. Calverley,et al.  Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease , 2003, Thorax.

[36]  D. Mannino,et al.  Low lung function and incident lung cancer in the United States: data From the First National Health and Nutrition Examination Survey follow-up. , 2003, Archives of internal medicine.

[37]  Steven Piantadosi,et al.  A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. , 2003, The New England journal of medicine.

[38]  D. Mannino,et al.  Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow up study , 2003, Thorax.

[39]  Don D. Sin,et al.  Why Are Patients With Chronic Obstructive Pulmonary Disease at Increased Risk of Cardiovascular Diseases?: The Potential Role of Systemic Inflammation in Chronic Obstructive Pulmonary Disease , 2003 .

[40]  W. Golisch,et al.  Ipratropium and lung health study. , 2003, American journal of respiratory and critical care medicine.

[41]  N. Anthonisen,et al.  Hospitalizations and mortality in the Lung Health Study. , 2002, American journal of respiratory and critical care medicine.

[42]  R. Zuwallack,et al.  A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease , 2002, European Respiratory Journal.

[43]  K F Hirji,et al.  Exact and asymptotic tests for homogeneity in several 2 x 2 tables. , 1999, Statistics in medicine.

[44]  T. Witek,et al.  Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease. , 1999, Life sciences.

[45]  L Goldman,et al.  Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments) , 1996, American journal of respiratory and critical care medicine.

[46]  John L. Hankinson,et al.  Standardization of Spirometry, 1994 Update. American Thoracic Society. , 1995, American journal of respiratory and critical care medicine.

[47]  P. Schnohr,et al.  Relation of ventilatory impairment and of chronic mucus hypersecretion to mortality from obstructive lung disease and from all causes. , 1990, Thorax.

[48]  N. Anthonisen.  Prognosis in chronic obstructive pulmonary disease: results from multicenter clinical trials. , 1989, The American review of respiratory disease.

[49]  M. B. Divertie,et al.  Clinical outcome of respiratory failure in patients requiring prolonged (> 24 hours) mechanical ventilation , 1986 .